Company: SXTPW
Filing Date: 2025-07-16
Form Type: 424B4
Source: 0001213900-25-064472
Chunk: 33

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-16
Form: 424B4
Chunk 33
---
 to the exemption from the registration requirements under the Securities Act of 1933, as amended (the “Securities Act”),
available to the Company under Section 4(a)(2) promulgated thereunder and Rule 506 of Regulation D promulgated under the Securities Act
due to the fact the offering of the January 2025 Warrants and the January 2025 Placement Agent Warrants thereunder did not involve a public
offering of securities.

The Company paid H.C. Wainwright & Co., LLC,
the placement agent in the February 2025 Offering, a cash transaction fee equal to 7.5% of the aggregate gross cash proceeds in the offering
and a management fee equal to 1.0% of the aggregate gross cash proceeds in the offering. In addition, the Company paid for certain non-accountable
expenses in the amount of $15,000 and a clearing fee in the amount of $10,000. The Company also issued to the placement agent warrants
to purchase up to 15,325 shares of common stock (the “January 2025 Placement Agent Warrants”). The January 2025 Placement
Agent Warrants have an exercise price equal to $6.382 per share and are exercisable upon issuance, or January 30, 2025, for twenty-four
months from the date of issuance, or January 30, 2027.

The Company received net proceeds of approximately
$804,346 from the offering, after deducting estimated offering expenses paid by the Company, including the placement agent fees. The Company
has used and intends to use the net proceeds from the offering for general corporate purposes, including working capital.

Supply Chain Updates

In February 2025, the FDA authorized the importation
of Kodatef from Australia, to cover any future disruption of Arakoda in the U.S. market. Kodatef is the branded version of tafenoquine
for malaria prevention approved by the TGA for use in Australia. The Company made this request of the FDA due to robust demand for Arakoda
in late 2024/early 2025, and the potential for delays in the completion of new lots of Arakoda currently being commercially validated
by our key supplier, PCI. Although we anticipate that new commercial Arakoda lots will enter the supply chain prior to the exhaustion
of existing inventory, Kodatef will be available to cover any shortage through a specialty pharmacy that already carries Arakoda, and